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Abstract
Background:  Bone metastases are a common cause of skeletal morbidity in patients with
advanced cancer. The pattern of skeletal morbidity is complex, and the number of skeletal
complications is influenced by the duration of survival. Because many patients with cancer die
before trial completion, there is a need for survival-adjusted methods to accurately assess the
effects of treatment on skeletal morbidity.
Methods: Recently, a survival-adjusted cumulative mean function model has been generated that
can provide an intuitive graphic representation of skeletal morbidity throughout a study. This
model was applied to the placebo-control arm of a pamidronate study in patients with malignant
bone disease from breast cancer.
Results: Analysis by bone lesion location showed that spinal metastases were associated with the
highest cumulative mean incidence of skeletal-related events (SREs), followed by chest and pelvic
metastases. Metastases located in the extremities were associated with an intermediate incidence
of SREs, and those in the skull were associated with the lowest incidence of SREs.
Conclusion:  Application of this model to data from the placebo arm of this trial revealed
important insight into the natural history of skeletal morbidity in patients with bone metastases.
Based on these observations, treatment for the prevention of SREs is warranted regardless of
lesion location except for metastases on the skull.
Background
Malignant bone disease involves a complex interplay
between tumor and bone, resulting in increased bone
resorption, stimulation of tumor growth in bone, and
decreased skeletal integrity[1] The development of bone
lesions is common in many types of advanced cancer,
including multiple myeloma and breast, prostate, and
lung cancers[2] For example, approximately 65% to 75%
of patients who develop metastatic disease from breast or
prostate cancer (the most common malignancies in
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women and men, respectively) will develop bone metas-
tases[2,3] Bone metastases from breast cancer have an
especially high propensity to cause skeletal complications
[4-7] Therefore, a large population of patients are at risk
for skeletal-related events (SREs) such as pathologic frac-
tures, spinal cord compression, severe bone pain requir-
ing palliative radiotherapy, loss of structural integrity and
impending fracture that requires surgery to bone, and
hypercalcemia of malignancy[1] Patients with advanced
breast cancer have a median survival of approximately 2
years after an initial diagnosis of bone metastases and are
at long-term risk for SREs. These patients experience an
average of 3 to 4 SREs every year in the absence of bisphos-
phonate therapy[1] However, the risk of experiencing sub-
sequent SREs increases approximately 2-fold after the first
incident; therefore, SREs usually occur in clusters and
become more frequent as the disease progresses[3,8] Skel-
etal morbidity also undermines patients' quality of life
and their ability to function in daily living, and fractures
have been associated with significantly reduced sur-
vival[9,10]
Currently, data on prognostic indicators for disease pro-
gression are available in patients with metastatic bone dis-
ease. For example, outcomes from exploratory analyses
indicate that the risk of skeletal complications in patients
with breast or prostate cancer is correlated with the rate of
bone resorption[11,12] Elevated baseline levels of N-ter-
minal telopeptide of type I collagen (NTX), a marker of
bone resorption, strongly correlated with the number of
SREs or death compared with low NTX levels. Patients
with NTX levels > 100 nmol/mmol creatinine were more
likely to experience an SRE and/or death than were
patients with NTX levels below this level (p ≤ 0.01). In
addition, the number of bone lesions has also been found
to influence the rate of skeletal complications from meta-
static bone disease. In exploratory analyses of 3 multi-
center, phase III trials in patients with metastatic bone
disease (n = 1,616) who were retrospectively stratified by
the number of bone lesions at baseline, patients with > 3
bone lesions had a higher skeletal morbidity rate than did
those with ≤ 3 bone lesions[13] Finally, the presence or
absence of pain at baseline may provide insight into a
patient's risk for SREs. Retrospective data from a phase III
trial suggest that patients with breast cancer and pain at
baseline have a higher mean annual incidence of SREs
than do patients with no pain at baseline[14]
Insight into the natural course of metastatic bone disease
could be enhanced by robust analyses for determining the
risk for SREs based on lesion sites. However, such analyses
are lacking. The placebo arm of a phase III pamidronate
registration study provides an opportunity to investigate
the natural history of skeletal morbidity in patients with
breast cancer[15] This trial is the largest database of
patients with bone metastases from breast cancer who
received placebo. The data from this study can serve to
illustrate the complicated patterns of skeletal morbidity in
patients with advanced breast cancer and provide a rich
database for testing the newer statistical methodology for
assessing skeletal morbidity, such as random-effects mod-
els. This methodology can accommodate variations in
event rates between patients, in contrast with previous
methodologies, which underestimated data variability
and could thereby inflate false-positive errors in treatment
comparisons[16] The analyses presented herein assessed
the potential prognostic significance of multiple variables
including age, location of metastases, and pain to deter-
mine survival and SREs. In addition, the relationship of
lesion site with risk for SREs was assessed to provide
insight on the risk for SREs in patients with advanced can-
cer.
Methods
Study Design
An exploratory analysis was performed using data from
the placebo-control arm of a 2-year, randomized, control-
led trial of pamidronate for the prevention of skeletal
morbidity in patients with bone metastases from breast
cancer who were receiving cytotoxic chemotherapy.
Patients were enrolled from January 1991 through March
1994, and trial results were published in December
1996[15] The rationale for the trial size was based on SRE
prevention by pamidronate versus placebo and has been
previously described[15] Briefly, patients with stage IV
breast cancer who had at least 1 osteolytic bone metastasis
were stratified by Eastern Cooperative Oncology Group
(ECOG) performance status and then randomized to
receive either pamidronate 90 mg (via 2-hour infusion) or
placebo every 3 to 4 weeks for 1 year. Patients who com-
pleted 1 year on study were allowed to continue on study
for an additional 1 year of therapy. The primary endpoint
was the time to first SRE, including pathologic fracture,
spinal cord compression, and the requirement for surgery
or radiation therapy to bone. Secondary endpoints
included incidence of SREs, change in bone pain and per-
formance status, and overall survival. All SREs were
included in the current analysis, in contrast with the orig-
inal study report in which a 21-day window between on-
study SREs was used. Lesion sites were assigned for bone
metastases on the basis of anatomic criteria: the pelvis
included any non-spinal lesion visible on a standard pel-
vic radiograph (including the approximate top one third
of the femur), the skull included any lesion on the skull
including the jaw, the chest included any lesions on the
chest, rib, or collar bone (excluding the spine), and the
extremities included any lesion in a region not described
by the other sites (eg, the arms, lower legs, hands, and
feet). The locations of SRE sites were determined by
review of medical records, which was necessary because of
the presence of multiple bone lesion sites in most
patients.BMC Cancer 2009, 9:272 http://www.biomedcentral.com/1471-2407/9/272
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Statistical Methodology
Associations between sites of bone lesions were assessed
using descriptive statistics. Cox proportional hazard mod-
els were used for univariate and multivariate analyses of
potential risk factors for reduced survival, time to first
SRE, and time to first pathologic fracture. All covariates
were included in a multivariate model, and then only var-
iables retaining significance (p < 0.05) were included in a
reduced multivariate model. Baseline variables consid-
ered included age (< 50 or ≥ 50 years old), time from diag-
nosis of cancer to study entry (years), time from diagnosis
of metastases to study entry (years), urinary hydroxypro-
line/creatinine ratio, serum bone-specific alkaline phos-
phatase (BALP) level (in units/L), Brief Pain Inventory
pain score, fracture history (yes/no), radiotherapy history
(yes/no), chemotherapy history (yes/no), hormonal ther-
apy history (< 2 or ≥ 2), ECOG performance status (< 2 or
2 to 3), estrogen- and progesterone-receptor status (nega-
tive, positive, or unknown), metastatic disease limited to
skeleton (yes/no), presence of lung or liver metastases
(yes/no), presence and quantity of primarily osteolytic,
osteoblastic, or mixed bone lesions (0, 1 to 2, or ≥ 3), and
lesion site. The survival distribution was assessed and
stratified by bone lesion site using Kaplan-Meier esti-
Table 1: Patient demographics and baseline disease characteristics
Characteristics Placebo group
(n = 195)
Age, mean years ± SD 56 ± 12
Patients < 50 years of age, n (%) 67 (34)
ECOG performance status, n (%)
0 – 1 128 (66)
2 – 3 67 (34)
Estrogen- and progesterone-receptor status, n (%)
Positive for at least 1 120 (62)
Other 75 (38)
Sites of metastasis, patients, n (%)
Bone, any 195 (100)
Bone as only metastatic site 117 (60)
Lung 30 (15)
Liver 29 (15)
Brain 1 (1)
Other 27 (14)
Time from primary to bone metastases diagnosis, median years ± SD 3.8 ± 4.5
Time from bone metastases to study entry, mean years ± SD 1.6 ± 1.7
Patients with bone lesions ≥ 1 cm in diameter, n (%)
1 lesion 82 (42)
2 lesions 71 (36)
≥ 3 lesions 42 (22)
Lesion types and numbers
1 – 2 osteolytic 104 (53)
≥ 3 osteolytic 91 (47)
0 osteoblastic 146 (75)
1 – 2 osteoblastic 37 (19)
≥ 3 osteoblastic 12 (6)
0 mixed lesions 28 (14)
1 – 2 mixed lesions
≥ 3 mixed lesions
61 (31)
106 (54)
Patients with SREs during the 3 months before study entry, n (%)
Palliative radiotherapy 57 (29)
Fracture 35 (18)
Pain scores, n (%)
0 27 (14)
1 – 3 76 (39)
4 – 9 92 (47)
Prior therapy regimens, n (%)
0 – 1 chemotherapy 80 (41)
2 – 3 chemotherapy 104 (53)
≥ 4 chemotherapy 11 (6)
0 – 1 hormonal therapy 102 (52)
2 – 3 hormonal therapy 77 (39)
≥ 4 hormonal therapy 16 (8)
SD = Standard deviation, ECOG = Eastern Cooperative Oncology Group, SRE = Skeletal-related event.
Adapted with permission from Hortobagyi et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone 
metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996;335:1785–1791. Copyright© 1996 Massachusetts Medical Society. All rights 
reserved[15]BMC Cancer 2009, 9:272 http://www.biomedcentral.com/1471-2407/9/272
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mates. For each bone lesion site, skeletal morbidity
parameters for that site were assessed using the survival-
adjusted cumulative mean function[17,18] Site-specific
SREs by each respective lesion site were evaluated in a sur-
vival-adjusted model. This model has previously been
used to capture patterns of skeletal morbidity during
bone-targeted therapy[16,19]
All SREs at each respective site were included in the cumu-
lative mean functions, and no event window was applied
to the SREs because all SREs contribute to the overall bur-
den of skeletal morbidity, even if they are related events.
Although hypercalcemia of malignancy is a clinically
important SRE associated with bone metastases, the ana-
tomic site responsible for its cause cannot be specified;
therefore, it was not included in the survival-adjusted
cumulative mean functions for each lesion site.
Results
Patient Demographics and Baseline Characteristics
Bone lesion data were available for all 195 patients in the
placebo group. Patient demographic and baseline disease
Table 2: Number of patients with at least 1 baseline lesion at each indicated location
Patients with additional lesions at indicated locations, n (%)
Lesion location Patients with ≥ 1 lesion at this location, n Pelvis Chest Spine Skull Other Only
Pelvis 178 -- 131 (74) 158 (89) 118 (66) 36 (20) 3 (2)
Chest 142 131 (92) -- 122 (86) 101 (71) 27 (19) 3 (2)
Spine 161 158 (98) 122 (76) -- 111 (69) 34 (21) 0
Skull 132 118 (89) 101 (77) 111 (84) -- 27 (21) 0
Other 42 36 (86) 27 (64) 34 (81) 27 (64) -- 0
Table 3: Univariate analysis for overall survival
Variable RR (95% CI) p value
Age ≥ 50 years 0.96 (0.68, 1.35) 0.802
ECOG performance status
2 – 3 versus 0 – 1 1.49 (1.06, 2.12) 0.024
Hydroxyproline/creatinine ratio (centered) 1.04 (1.02, 1.07) 0.001
Bone-specific alkaline phosphatase (U/L) 1.00 (1.00, 1.01) 0.415
Estrogen-receptor status versus negative
Positive 0.67 (0.42, 1.06) 0.085
Unknown 0.96 (0.64, 1.44) 0.857
Progesterone-receptor status versus negative
Positive 0.61 (0.40, 0.93) 0.022
Unknown 0.70 (0.49, 0.99) 0.047
Sites of metastasis (yes versus no)
Bone as only metastatic site 0.90 (0.65, 1.26) 0.553
Lung 1.43 (0.89, 2.30) 0.139
Liver 1.12 (0.69, 1.79) 0.653
Time from diagnosis of bone metastases to study entry, years 1.10 (1.00, 1.21) 0.059
Time from cancer diagnosis to study entry, years 
Lesion characteristics and numbers
1.00 (0.95, 1.03) 0.630
≥ 3 osteolytic versus < 3 osteolytic 1.29 (0.93, 1.80) 0.128
1 – 2 osteoblastic versus no osteoblastic 0.98 (0.65, 1.48) 0.935
≥ 3 osteoblastic versus no osteoblastic 0.75 (0.62, 0.91) 0.003
1 – 2 mixed versus no mixed 0.81 (0.48, 1.36) 0.423
≥ 3 mixed versus no mixed 1.03 (0.67, 1.58) 0.896
Prior fracture (yes versus no) 1.18 (0.78, 1.77) 0.440
Pain scores (centered) 1.07 (1.01, 1.13) 0.034
Prior chemotherapy (yes versus no) 1.85 (0.59, 5.87) 0.294
≥ 2 prior hormonal therapies (yes versus no) 1.31 (0.94, 1.82) 0.110
Prior radiotherapy (yes versus no) 1.15 (0.80, 1.64) 0.464
Values in bold represent statistically significant correlations.
RR = Relative risk, CI = Confidence interval, ECOG = Eastern Cooperative Oncology Group, U = Units.BMC Cancer 2009, 9:272 http://www.biomedcentral.com/1471-2407/9/272
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characteristics are shown in Table 1[15] The skeleton was
the only site of metastasis in 60% of patients. Consistent
with the fact that no bisphosphonates had yet been
approved in this setting at the time, most patients had
been diagnosed with bone metastases more than 1 year
before study entry, but none had received prior bisphos-
phonate therapy. Most patients also had bone lesions at
multiple anatomic locations. The majority of patients
(64%) were found to have bone metastases in the pelvis,
spine, and chest (Table 2).
Risk Factors for Skeletal Morbidity and Death
For overall survival, all of the variables assessed in both
univariate and full multivariate analyses and their associ-
ated relative risk ratios are shown in Tables 3 and 4. At
trial completion, 43% of patients were alive. Hydroxypro-
line/creatinine ratio (centered) and positive progesterone-
receptor status were the only variables to significantly cor-
relate with overall survival in both univariate (p = 0.001
and p = 0.022, respectively) and full multivariate analyses
(p = 0.001 and p = 0.050, respectively). The same variables
used for overall survival were included in the univariate
and full multivariate analyses to assess prognostic factors
for experiencing a first SRE (Tables 5 and 6). At trial com-
pletion, 56% of patients had experienced at least 1 SRE.
Pain scores and prior radiotherapy significantly correlated
with risk of first SRE in both univariate (p < 0.001 for all)
and full multivariate analyses (p < 0.001 for pain; p =
0.018 for prior radiotherapy).
The reduced multivariate models included all significant
variables from the multivariate models. For overall sur-
vival (Figure 1A), increased time from diagnosis of cancer
to study entry, a higher hydroxyproline/creatinine ratio, a
history of 2 or more prior hormonal therapies, and the
presence of lung metastases significantly correlated with
decreased survival duration (p ≤ 0.034) in the reduced
model. Increased time from diagnosis of cancer to diagno-
sis of bone metastases and positive progesterone-receptor
status significantly correlated with increased survival (p ≤
0.011). For first SRE, a higher pain score, prior radiother-
apy, and the presence of 3 or more osteolytic lesions cor-
related with a significantly increased risk (p ≤ 0.039;
Figure 1B). For pathologic fractures, a higher level of
BALP, a higher pain score, and a poorer performance sta-
tus (ECOG 2 or 3) significantly correlated with increased
Table 4: Full multivariate analysis for overall survival
Variable RR (95% CI) p value
Age ≥ 50 years 1.18 (0.78, 1.78) 0.434
ECOG performance status
2 – 3 versus 0 – 1 1.15 (0.76, 1.76) 0.507
Hydroxyproline/creatinine ratio (centered) 1.06 (1.02, 1.10) 0.001
Bone-specific alkaline phosphatase (U/L) 1.00 (0.99, 1.01) 0.471
Estrogen-receptor status versus negative
Positive 0.78 (0.44, 1.40) 0.406
Unknown 1.53 (0.67, 3.50) 0.314
Progesterone-receptor status versus negative
Positive 0.58 (0.33, 1.00) 0.050
Unknown 0.51 (0.24, 1.07) 0.074
Sites of metastasis (yes versus no)
Bone as only metastatic site 0.75 (0.44, 1.29) 0.301
Lung 1.49 (0.733, 3.01) 0.273
Liver 0.84 (0.435, 1.61) 0.593
Time from diagnosis of bone metastases to study entry, years 1.21 (1.05, 1.38) 0.008
Time from cancer diagnosis to study entry, years 0.83 (0.72, 0.95) 0.008
Lesion characteristics and numbers
≥ 3 osteolytic versus < 3 osteolytic 1.34 (0.92, 1.95) 0.128
1 – 2 osteoblastic versus no osteoblastic 1.19 (0.74, 1.92) 0.471
≥ 3 osteoblastic versus no osteoblastic 0.79 (0.36, 1.74) 0.559
1 – 2 mixed versus no mixed 0.64 (0.36, 1.16) 0.140
≥ 3 mixed versus no mixed 0.63 (0.35, 1.12) 0.112
Prior fracture (yes versus no) 0.99 (0.58, 1.67) 0.964
Pain scores (centered) 1.03 (0.96, 1.11) 0.406
Prior chemotherapy (yes versus no) 1.54 (0.46, 5.16) 0.484
≥ 2 prior hormonal therapies (yes versus no) 1.61 (1.08, 2.40) 0.020
Prior radiotherapy (yes versus no) 0.75 (0.47, 1.20) 0.230
Values in bold represent statistically significant correlations.
RR = Relative risk, CI = Confidence interval, ECOG = Eastern Cooperative Oncology Group, U = Units.BMC Cancer 2009, 9:272 http://www.biomedcentral.com/1471-2407/9/272
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risk (p ≤ 0.012; Figure 1B). For radiotherapy to bone, a
higher pain score and prior radiotherapy correlated with
an increased risk (p ≤ 0.010; Figure 1B).
Cumulative Mean Function for Bone Lesion Locations
Median survival was similar for each of the bone lesion
groups and was approximately 15 months. Spinal lesions
were associated with the highest incidence of SREs and
had a cumulative mean incidence of approximately 0.65
SREs per year (Figure 2A). The most common spinal SREs
were palliative radiotherapy and fractures. Thoracic and
pelvic lesions were associated with a slightly lower inci-
dence of SREs and had a cumulative mean incidence of
approximately 0.50 SREs per year (Figures 2B and 2C,
respectively). Lesions located on the extremities were
associated with an intermediate incidence of SRE and had
a cumulative mean incidence of approximately 0.25 SREs
per year (Figure 2D). Lesions located in the skull were
associated with the lowest incidence of SREs and had a
cumulative mean incidence of < 0.1 SRE per year (Figure
2E). The most common SRE experienced in the skull was
the need for radiotherapy.
The incidence of SREs for the overall patient population
was determined based on SRE location. Spinal lesions car-
ried the highest cumulative mean incidence of SREs, fol-
lowed by lesions in the chest and pelvis (Figure 3A).
Lesions in the chest and spine carried the highest cumula-
tive mean incidence of pathologic fractures at these sites,
whereas fractures were less common in the pelvis and rare
in the skull or extremities (Figure 3B). Although radiation
to bone was the most common SRE for skull lesions, the
overall incidence of radiation to bone in the skull was
lowest. The incidence of radiation to bone was highest for
pelvic and spinal lesions (Figure 3C).
Discussion
The development of bone metastases is common in many
advanced cancers including cancers of the breast, prostate,
and lung[9] After diagnosis of bone metastases, the
median survival varies among different tumor types but
can be measured in months for patients with advanced
lung cancer or years for patients with advanced breast or
prostate cancer. These patients are at long-term risk for
developing painful and potentially debilitating SREs that
Table 5: Univariate analysis for first skeletal-related event
Variable RR (95% CI) p value
Age ≥ 50 years 0.94 (0.63, 1.40) 0.760
ECOG performance status
2 – 3 versus 0 – 1 1.81 (1.21, 2.72) 0.004
Hydroxyproline/Creatinine ratio (centered) 1.00 (0.97, 1.04) 0.921
Bone-specific alkaline phosphatase, U/L 1.01 (1.00, 1.01) 0.204
Estrogen-receptor status versus negative
Positive 0.56 (0.34, 0.92) 0.023
Unknown 0.89 (0.58, 1.36) 0.580
Progesterone-receptor status versus negative
Positive 0.62 (0.38, 1.01) 0.053
Unknown 0.78 (0.52, 1.16) 0.214
Sites of metastasis (yes versus no)
Bone as only metastatic site 0.84 (0.57, 1.24) 0.392
Lung 1.32 (0.77, 2.29) 0.317
Liver 1.26 (0.75, 2.13) 0.379
Time from diagnosis of bone metastases to study entry, years 1.00 (0.95, 1.04) 0.912
Time from cancer diagnosis to study entry, years 1.00 (0.96, 1.04) 0.947
Lesion characteristics and numbers
≥ 3 osteolytic versus < 3 osteolytic 1.92 (1.29, 2.84) 0.001
1 – 2 osteoblastic versus no osteoblastic 1.28 (0.82, 2.02) 0.282
≥ 3 osteoblastic versus no osteoblastic 0.39 (0.32, 0.50) < 0.001
1 – 2 mixed versus no mixed 1.16 (0.64, 2.09) 0.624
≥ 3 mixed versus no mixed 1.26 (0.77, 2.06) 0.352
Prior fracture (yes versus no) 1.78 (1.12, 2.81) 0.014
Pain scores (centered) 1.29 (1.19, 1.40) < 0.001
Prior chemotherapy (yes versus no) 0.89 (0.32, 2.48) 0.816
≥ 2 prior hormonal therapies (yes versus no) 1.11 (0.75, 1.63) 0.605
Prior radiotherapy (yes versus no) 2.02 (1.35, 3.02) < 0.001
Values in bold represent statistically significant correlations.
RR = Relative risk, CI = Confidence interval, ECOG = Eastern Cooperative Oncology Group, U = Units.BMC Cancer 2009, 9:272 http://www.biomedcentral.com/1471-2407/9/272
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can negatively influence their quality of life and decrease
their duration of survival. Patients with metastatic bone
disease will generally experience 3 to 4 SREs each year,[1]
although the occurrence of these skeletal complications is
not regular. Skeletal-related events are known to occur
more frequently during periods of disease progression
and occur more often in temporal clusters as the cancer
becomes more advanced. Obtaining a greater understand-
ing of the natural course of disease progression in patients
with metastatic bone disease may help identify patients
who are at higher risk for SREs and may benefit the most
from bone-directed therapies such as bisphosphonates, or
who may require close monitoring and surveillance.
Information regarding prognostic indicators for disease
progression is currently available for patients with meta-
static bone disease. For example, variables including prior
SRE, number of lesion sites, the presence of pain, and high
levels of bone resorption are known to affect patients' risk
for SREs. In the current study, reduced multivariate analy-
ses confirmed that the presence of 3 or more osteolytic
lesions correlated with an increased risk for SREs. Moreo-
ver, multivariate analyses demonstrated that higher pain
scores and prior radiotherapy also correlated with an
increased risk for SREs. This exploratory natural history
study of bone metastases was limited by the available data
and only produced statistical associations between varia-
bles. The dataset used in these analyses was from the larg-
est documented placebo-controlled trial of patients with
bone metastases from breast cancer. Therefore, the evalu-
ated patients were not a random sample of patients with
bone metastases, but the best available patients. Moreo-
ver, the multiple comparisons used in this study were not
prospectively defined at the time of patient enrollment;
therefore, there is inconsistency in the number of patients
with available data for each variable. Further prospective
studies would be needed to confirm the findings from this
study. Such trials are unlikely to be initiated, however, as
bisphosphonate treatment of patients with bone metas-
tases is now standard of care and a placebo-controlled
trial may be unethical.
Although information on prognostic factors for SREs
based on baseline disease characteristics is available, data
regarding patients' risk for SREs based on the natural
course of malignant bone disease are lacking. The data
Table 6: Full multivariate analysis for first skeletal-related event
Variable RR (95% CI) p value
Age ≥ 50 years 1.12 (0.69, 1.83) 0.651
ECOG performance status
2 – 3 versus 0 – 1 1.33 (0.78, 2.25) 0.296
Hydroxyproline/Creatinine ratio (centered) 0.97 (0.92, 1.03) 0.292
Bone-specific alkaline phosphatase, U/L 1.01 (1.00, 1.02) 0.083
Estrogen-receptor status versus negative
Positive 0.94 (0.50, 1.76) 0.838
Unknown 0.91 (0.35, 2.36) 0.844
Progesterone-receptor status versus negative
Positive 0.80 (0.41, 1.55) 0.506
Unknown 1.19 (0.51, 2.81) 0.685
Sites of metastasis (yes versus no)
Bone as only metastatic site 0.81 (0.45, 1.44) 0.467
Lung 1.49 (0.70, 3.20) 0.306
Liver 0.98 (0.48, 1.99) 0.960
Time from diagnosis of bone metastases to study entry, years 1.01 (0.84, 1.20) 0.992
Time from cancer diagnosis to study entry, years 0.97 (0.91, 1.04) 0.395
Lesion characteristics and numbers
≥ 3 osteolytic versus < 3 osteolytic 1.53 (0.96, 2.44) 0.071
1 – 2 osteoblastic versus no osteoblastic 1.70 (1.01, 2.86) 0.045
≥ 3 osteoblastic versus no osteoblastic 0.70 (0.24, 2.08) 0.525
1 – 2 mixed versus no mixed 1.16 (0.57, 2.33) 0.687
≥ 3 mixed versus no mixed 1.47 (0.72, 3.01) 0.291
Prior fracture (yes versus no) 0.83 (0.44, 1.58) 0.577
Pain scores (centered) 1.27 (1.15, 1.40) < 0.001
Prior chemotherapy (yes versus no) 1.07 (0.33, 3.41) 0.915
≥ 2 prior hormonal therapies (yes versus no) 1.00 (0.62, 1.62) 1.000
Prior radiotherapy (yes versus no) 1.84 (1.11, 5.03) 0.018
Values in bold represent statistically significant correlations.
RR = Relative risk, CI = Confidence interval, ECOG = Eastern Cooperative Oncology Group, U = Units.BMC Cancer 2009, 9:272 http://www.biomedcentral.com/1471-2407/9/272
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Forest plot of relative risks in patients with bone metastases from breast cancer Figure 1
Forest plot of relative risks in patients with bone metastases from breast cancer. Significant covariates for (A) 
overall survival, (B) first SRE, first pathologic fracture, and first radiation to bone. The relative risk for each covariate was 
derived from reduced multivariate analyses. Lines represent 95% confidence intervals. PR = Progesterone receptor, SRE = 
Skeletal-related event, BALP = Bone-specific alkaline phosphatase, ECOG = Eastern Cooperative Oncology Group.BMC Cancer 2009, 9:272 http://www.biomedcentral.com/1471-2407/9/272
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presented herein demonstrate that, in addition to the
identified prognostic factors, the complex pattern of skel-
etal involvement associated with metastatic bone disease
is clinically meaningful in determining the risk for SREs.
Specifically, the anatomic site of skeletal lesions can pro-
vide insight into the risk of skeletal morbidity at the lesion
site. For example, patients with pelvic, spinal, and chest
lesions can be considered high risk for SREs. These lesions
were associated with the highest cumulative mean inci-
dence of SREs per year, with the spine demonstrating the
highest risk of SREs. In contrast, lesions on skeletal sites
that are not weight-bearing, including the skull and
extremities, are associated with fewer SREs. Although the
location of skeletal lesions affected the cumulative mean
incidence of SREs, it did not appear to affect survival,
because the median overall survival was approximately 15
months for all patients regardless of lesion site. However,
this analysis is limited by the presence of multiple meta-
static sites in the majority of patients, and, while the
effects of each lesion site on SRE risk could be evaluated
separately by limiting the assessed SREs to those occurring
in that lesion site, this type of adjustment could not be
made for the survival outcome.
Patients with metastatic bone disease are at a long-term
risk for SREs that can undermine patients' functional
independence. Identifying those patients who may be
more susceptible to potentially debilitating SREs may
help to optimize bisphosphonate therapy and maintain
their quality of life throughout the course of disease. This
study indicates that patients with lesions to the pelvis,
spine, or chest are at increased risk of SREs, and prior stud-
ies demonstrated that patients with an SRE are at
increased risk of subsequent SREs[20] Bisphosphonates
reduce the risk of SREs in patients with bone lesions from
solid tumors or multiple myeloma and provide continu-
Time course of cumulative mean events of skeletal-related events (SREs) in patients with bone metastases from breast cancer Figure 2
Time course of cumulative mean events of skeletal-related events (SREs) in patients with bone metastases 
from breast cancer. The incidence of SREs was assessed for patients with (A) spinal lesions, (B) thoracic lesions, (C) pelvic 
lesions, (D) lesions of the extremities, or (E) skull lesions.BMC Cancer 2009, 9:272 http://www.biomedcentral.com/1471-2407/9/272
Page 10 of 12
(page number not for citation purposes)
ous treatment benefits to patients even after the develop-
ment of an SRE[7,20-23] In patients with bone metastases
from breast cancer, zoledronic acid reduced the risk of a
second SRE by 31% compared with pamidronate (p  =
0.045)[23] Moreover, in patients with prostate or lung
cancer, zoledronic acid reduced the risk of a second SRE
by 40% (p = 0.028) and 31% (p = 0.0009), respectively,
compared with placebo[7,22] The combination of these
prior findings and the current results indicates that early
and continuous bisphosphonate treatment is necessary to
delay time to first SRE and reduce the overall occurrence
of SREs. Additionally, these analyses underscore the
importance of treating bone lesions, especially for
patients with pelvis, spine, or rib lesions, and provide
important insight into the natural history of bone disease
from advanced cancers. The insights gained from these
exploratory analyses and previous studies[11,16,24] pro-
vide the basis for developing a predictive nomogram for
assessing bone morbidity, which we plan to test using the
databases from the phase III zoledronic acid clinical trials.
Conclusion
Skeletal complications from bone metastases can under-
mine quality of life and may be life-limiting in patients
with advanced cancer. Although metastases can occur
throughout the skeleton, some sites may be associated
with a higher rate of symptoms. Retrospective analysis of
the placebo-controlled arm of a pamidronate study in
patients with bone metastases from breast cancer revealed
that spinal and chest metastases were associated with the
highest risk of SREs. In contrast, metastases located in the
skull correlated with the lowest risk of SREs. These results
Time course of survival-adjusted cumulative mean function of skeletal-related events (SREs) in patients with bone metastases  from breast cancer Figure 3
Time course of survival-adjusted cumulative mean function of skeletal-related events (SREs) in patients with 
bone metastases from breast cancer. Lesion locations were determined for patients with (A) any SRE, (B) pathologic frac-
tures, and (C) radiation to bone.BMC Cancer 2009, 9:272 http://www.biomedcentral.com/1471-2407/9/272
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provide insight into the natural history of SREs in patients
with bone metastases. Moreover, these findings suggest
that patients with bone metastases should be treated with
bone-targeted therapies to prevent SREs regardless of
lesion location.
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